| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/27/2004 | EP1470123A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, related compositions and methods |
| 10/27/2004 | EP1470122A1 Rho-kinase inhibitors |
| 10/27/2004 | EP1470121A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 10/27/2004 | EP1470120A1 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives |
| 10/27/2004 | EP1470119A1 Benzothiophene compounds having antiinfective activity |
| 10/27/2004 | EP1470115A1 Treatment of male sexual dysfunction |
| 10/27/2004 | EP1470113A1 Pyrimidinone viral polymerase inhibitors |
| 10/27/2004 | EP1470112A1 Substituted pyridazinones as inhibitors of p38 |
| 10/27/2004 | EP1470109A1 Metabolites of (3- [(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl -phenoxy)-acetic acid |
| 10/27/2004 | EP1470108A1 1,4-dihydropyridine and pyridine compounds as calcium channel blockers |
| 10/27/2004 | EP1470107A2 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists |
| 10/27/2004 | EP1470104A2 Novel compounds that inhibit factor xa activity |
| 10/27/2004 | EP1470103A1 Amidoacetonitrile derivatives |
| 10/27/2004 | EP1470102A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps) |
| 10/27/2004 | EP1470101A1 New opioid derivative |
| 10/27/2004 | EP1469938A1 Apparatus and process for preparing crystalline particles |
| 10/27/2004 | EP1469898A1 A method and system for treating an atrial arrhythmia |
| 10/27/2004 | EP1469886A2 Pharmaceutical composition |
| 10/27/2004 | EP1469885A1 Parenteral composition of paracetamol |
| 10/27/2004 | EP1469884A1 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders |
| 10/27/2004 | EP1469877A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies |
| 10/27/2004 | EP1469876A2 Antimicrobial cationic peptides and formulations thereof |
| 10/27/2004 | EP1469873A2 Peptidomimetic inhibitors of post-proline cleaving enzymes |
| 10/27/2004 | EP1469866A1 Cycloglycans suitable to inhibit mammalian infection |
| 10/27/2004 | EP1469865A2 Hemostatic compositions and methods for controlling bleeding |
| 10/27/2004 | EP1469864A1 Compounds useful as a-3 adenosine receptor agonists |
| 10/27/2004 | EP1469863A2 Selective s1p1/edg1 receptor agonists |
| 10/27/2004 | EP1469862A2 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions |
| 10/27/2004 | EP1469861A1 Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen |
| 10/27/2004 | EP1469860A2 Anti-cancer combination and use thereof |
| 10/27/2004 | EP1469859A1 Use of polyunsaturated ketones for the treatment of psoriasis |
| 10/27/2004 | EP1469858A1 Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation |
| 10/27/2004 | EP1469857A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis |
| 10/27/2004 | EP1469856A2 8-heteroaryl xanthine adenosine a sb 2b /sb receptor antagonists |
| 10/27/2004 | EP1469855A2 Methods of treating patients suffering from movement disorders |
| 10/27/2004 | EP1469854A1 Condensed heterocyclic compounds |
| 10/27/2004 | EP1469853A1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-d-pyrimidine for treating of urinary incontinence |
| 10/27/2004 | EP1469852A2 Nitric oxide donors for treatment of disease and injury |
| 10/27/2004 | EP1469851A1 Melanocortin receptor agonists |
| 10/27/2004 | EP1469850A1 Method of treating sexual dysfunctions with delta opioid receptor agonist compounds |
| 10/27/2004 | EP1469849A1 Treating stress response with chemokine receptor ccr5 modulators |
| 10/27/2004 | EP1469848A1 Sedative non-benzodiazepine formulations |
| 10/27/2004 | EP1469847A1 Combinations comprising epothilones and anti-metabolites |
| 10/27/2004 | EP1469846A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 10/27/2004 | EP1469845A2 Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases |
| 10/27/2004 | EP1469844A2 Method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as aids |
| 10/27/2004 | EP1469843A1 Composition for pharmaceutical or dietetic use for combating hair loss |
| 10/27/2004 | EP1469842A2 Bicyclic cb2 cannabinoid receptor ligands |
| 10/27/2004 | EP1469841A1 Alpha 2 delta ligands to treat tinnitus |
| 10/27/2004 | EP1469839A2 Transmucosal delivery of proton pump inhibitors |
| 10/27/2004 | EP1469838A1 Manufacture of oral dosage forms delivering both immediate release and sustained release drugs |
| 10/27/2004 | EP1469836A1 Increased-dosage nelfinavir tablet and method of making same |
| 10/27/2004 | EP1469835A2 Stable salts of o-acetylsalicylic acid containing basic amino acids ii |
| 10/27/2004 | EP1469834A1 Multi-stage oral drug controlled-release system |
| 10/27/2004 | EP1469833A2 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| 10/27/2004 | EP1469831A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors |
| 10/27/2004 | EP1469830A2 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| 10/27/2004 | EP1469829A2 Immediate release dosage forms containing solid drug dispersions |
| 10/27/2004 | EP1469828A2 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same |
| 10/27/2004 | EP1469827A2 Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate |
| 10/27/2004 | EP1469823A2 Cosmetic or dermatological use of vitamin a or the esters thereof in combination with a partly methylated beta-cyclodextrin |
| 10/27/2004 | EP1469810A2 Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders |
| 10/27/2004 | EP1469743A1 Stable hygroscopic compositions and methods for stabilizing hygroscopic ingredients |
| 10/27/2004 | EP1469717A2 Triple transgenic mouse model of alzheimer's disease |
| 10/27/2004 | EP1373263B1 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 10/27/2004 | EP1315728B1 Process for the preparation of vitronectin receptor antagonists |
| 10/27/2004 | EP1272456B1 Hydrazide and alkoxyamide angiogenesis inhibitors |
| 10/27/2004 | EP1253906B1 Cosmetic preparations containing waltheria indica extracts and ferulic acid |
| 10/27/2004 | EP1246791B1 Aminomethyl-phenyl-cyclohexanone derivatives |
| 10/27/2004 | EP1244457B1 Use of modulators of annexin for the manufacture of a medicament for the treatment and/or prevention of arthritis and arthritic diseases |
| 10/27/2004 | EP1242418B1 Antidiabetic thiazolidinediones and their preparation |
| 10/27/2004 | EP1212061B1 Injectable buprenorphine microparticle compositions and their use in reducing consumption of heroin and alcohol |
| 10/27/2004 | EP1204407B1 Implantable active ingredient depot |
| 10/27/2004 | EP1150952B1 Indole derivatives and their use as mcp-1 receptor antagonists |
| 10/27/2004 | EP1137424B9 Preparation which contains oligosaccharides and probiotics |
| 10/27/2004 | EP1105391B1 Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for thier preparation |
| 10/27/2004 | EP1085858B1 Transdermal therapeutic system for the administration of candesartan |
| 10/27/2004 | EP1073428B1 Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases |
| 10/27/2004 | EP1037629B1 Combination of a retinoic acid metabolism blocking agent and a tocophereol |
| 10/27/2004 | EP1005453B1 Substituted benzene compounds as antiproliferative lowering agents |
| 10/27/2004 | EP0998577B1 Conjugates of transporter peptides and nucleic acid analogs, and their use |
| 10/27/2004 | EP0970073B1 Process for preparing eprosartan |
| 10/27/2004 | EP0960108B1 Matrix metalloproteinase inhibitors |
| 10/27/2004 | EP0957100B1 Diamine derivatives and pharmaceutical containing the same |
| 10/27/2004 | EP0918461B1 Methods of treating asthma with o-desulfated heparin |
| 10/27/2004 | EP0914091B9 Ethene containing solutions and use thereof in methods of therapy or prophylaxis |
| 10/27/2004 | EP0910362B1 Oxa acids and related compounds for treating skin conditions |
| 10/27/2004 | EP0900565B1 Patch containing isosorbide dinitrate |
| 10/27/2004 | EP0897427B1 Polysaccharide precipitation process |
| 10/27/2004 | EP0866793B1 Nitroimidazole antibacterial compounds and methods of use thereof |
| 10/27/2004 | EP0831791B1 Delivery of drugs to the lower gi tract |
| 10/27/2004 | EP0763052B1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION |
| 10/27/2004 | EP0759992B1 Human papilloma virus inhibition by a hairpin ribozyme |
| 10/27/2004 | CN1541278A Novel molecular target for neurotoxicity |
| 10/27/2004 | CN1541277A Method of determing chemotherapeutic regimen based on glutachione-S-transferase pi expression |
| 10/27/2004 | CN1541269A Human protooncogene KG-zo and protein encoded therein |
| 10/27/2004 | CN1541262A Hops extracts, method for prodn. and use |
| 10/27/2004 | CN1541226A Antibodes specific for CD44V6 |
| 10/27/2004 | CN1541220A 17 alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
| 10/27/2004 | CN1541219A Tricyclic imidazopyridines |